The scientific literature has demonstrated that glutamine is one of the main beneficial amino acids. It plays an important role in gut microbiota and immunity. This paper provides a critical overview of experimental studies (in vitro, in vivo, and clinical) investigating the efficacy of glutamine and its effect on gut microbiota. As a result of this review, we have summarized that glutamine could affect gut microbiota via different mechanisms including the reduction in the ratio of Firmicutes to Bacteroidetes, with the activation of NF-κB and PI3K-Akt pathways, reducing the intestinal colonization (Eimeria lesions) and bacterial overgrowth or bacterial translocation, increasing the production of secretory immunoglobulin A (SIgA) and immunoglobulin A+ (IgA+) cells in the intestinal lumen, and decreasing asparagine levels. The potential applications of glutamine on gut microbiota include, but are not limited to, the management of obesity, bacterial translocation and community, cytokines profiles, and the management of side effects during post-chemotherapy and constipation periods. Further studies and reviews are needed regarding the effects of glutamine supplementation on other conditions in humans.
1 October 2020 in Science of The Total Environment
Salmonellosis is one of the major public health concerns in Bahrain as it has increased rapidly during the past few years. This study aims to determine the prevalence of salmonellosis in children and the possible risk factors such as age, geographical area, nationality, gender, unsafe drinking water, infant born weight and gastrointestinal disease. The cases of salmonellosis in children reported by the Ministry of Health of Bahrain ranged from 21 to 26 per 100,000 population during the period 2012–2016. Salmonellosis cases were geographically concentrated in the capital and northern regions. Statistical analysis showed a significant difference in the number of salmonellosis cases between Bahrainis and non-Bahrainis based on region, and gender (p < 0.001). In the Bahraini cohort, there was an association between the increase of cases and the number of gastrointestinal disease-related deaths (p < 0.05). In addition, unsafe water (over the level of 2.14%) and low-birth weight (<3.100 g) were associated, but not statistically significant (p = 0.086 and p = 0.126, respectively) with the increase of salmonellosis cases. Despite the decline in the number of cases, the results of this study contribute to the understanding of the epidemiology of Salmonella in humans and this, in turn, will help develop and implement preventative measures.
Introduction: Ovarian cancer remains one of the most prevalent and lethal gynecological malignancies globally, necessitating the exploration of novel therapeutic agents. Baicalein, a naturally occurring flavonoid, possesses potent antioxidant and anti-inflammatory properties and has recently gained attention for its anticancer potential. This study aimed to elucidate the anticancer efficacy and underlying molecular mechanisms of baicalein in human ovarian carcinoma PA-1 cells through comprehensive in vitro and in silico approaches. Methods: PA-1 cells were exposed to increasing concentrations of baicalein, and cytotoxicity was assessed using the MTT assay. Apoptotic induction was evaluated by measuring mitochondrial membrane potential (MMP), reactive oxygen species (ROS) induction, and nuclear morphological changes using DAPI, Hoechst/PI, and AO/EB staining. Cell cycle checkpoints were analyzed by flow cytometry. Apoptosis-related genes (p53, Bax, Puma, Noxa, and Bcl-2) expression was quantified using qRT-PCR. In silico molecular docking was performed using PyRx to predict interactions with key apoptotic proteins, while SwissADME was employed to assess pharmacokinetic properties and drug-likeness. Results: Baicalein significantly reduced PA-1 cell viability in a concentration-dependent manner and induced pronounced morphological changes characteristic of apoptosis. Treatment resulted in elevated ROS production, loss of MMP, nuclear condensation, and S-phase cell cycle arrest. Gene expression analysis demonstrated significant upregulation of pro-apoptotic markers (p53, Bax, Puma, and Noxa) alongside decreased expression of the anti-apoptotic gene Bcl-2. Molecular docking studies revealed favorable binding affinities of baicalein with apoptosis-regulating proteins, and SwissADME analysis confirmed acceptable drug-likeness and pharmacokinetic profiles. Discussion: These findings showed that baicalein induces apoptosis in ovarian cancer PA-1 cells via a ROSmediated, mitochondria-dependent pathway. Conclusion: This study highlights the potential of baicalein as a promising lead compound for the development of anticancer therapeutics.